Evaxion A/S has appointed Dr. Helen Tayton-Martin as its new CEO, effective November 24, 2025. She brings extensive biotech experience from Adaptimmune and will lead the company's AI-powered vaccine development strategy.

Questex's Fierce Pharma Week will feature celebrities like Jamie-Lynn Sigler, James Van Der Beek, and Selma Blair sharing personal health stories, alongside pharmaceutical industry leaders discussing innovation and patient experiences.

The LAG-3 next-generation therapies market is expected to grow significantly in the coming years due to the potential entry of major LAG-3 candidates, increase in incident cases of various solid tumors, and improvement in patient outcomes.

The FDA is expected to make several landmark decisions in Q3, including approvals for treatments for schizophrenia, PTSD, and liver disease. These decisions could be impacted by recent biotechnology acquisitions.

Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.